{"id":"W2635951006","doi":"10.1056/nejmoa1613493","title":"First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer","year":2017,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2575,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Nivolumab; Docetaxel; Medicine; Oncology; Lung cancer; Chemotherapy; Internal medicine; Lung; Cancer; Stage (stratigraphy); Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}